Generic competition dents sales at Astra - UPDATE
26th Jul 2012 16:37
Gross margins at AstraZeneca held up well in the first quarter, but the pharmaceuticals giant saw sales tumble as generic competition to its drugs ramped up. Astra, which reports in dollars, saw total revenues in the three months to June 30th of $6.66bn, a 21% drop on 2011 and well below the consen
Read moreLondon midday: Stocks jump after Draghi comments
26th Jul 2012 11:43
- Draghi pledges to do whatever it takes - Greece still on investors' minds - Markets digest a ton of results After a pretty flat start on the back of a flurry of mixed corporate earnings in London, the Footsie rocketed in late morning after some comments from the European Central Bank (ECB) Presid
Read moreAstra's profits fall as generics swallow market share
26th Jul 2012 08:03
AstraZeneca, the UK's second biggest pharma company, is sticking to its full year guidance despite a continuing slump in profits as competition from generic drugs heats up. Astra, which reports in dollars, saw core profits before tax of $2.164bn between April and June, a decline on 2011 of 33%, or
Read moreBig caps round-up: Shell, Lloyds, BG Group ...
26th Jul 2012 07:30
An extraordinary number of FTSE 100 companies released updates on Thursday morning. This is a round-up of the key points for each. AstraZeneca: Revenue for the second quarter was $6,660m, down 18% at constant exchange rates (CER). Core earnings per share (EPS) was $1.53 in the second quarter, a 6%
Read moreThursday preview: Deluge of updates expected
25th Jul 2012 16:26
Suspicions that the City is trying to get all of its business out of the way before the onset of the London Olympics are supported by the barrage of company results due on Thursday. Among the heavyweights expected to report are Astra, BG, BSkyB, Centrica, Compass, Capital Shopping, Intertek, Invens
Read moreWeek ahead: Hammerson, ARM, AstraZeneca
20th Jul 2012 10:30
Next week looks like a busy week for corporate trading statements and results, as blue chips begin to update the market on their performance at the interim stage, including FTSE 100 peers Hammerson, ARM Holdings and AstraZeneca. Retail-focused real estate investment trust (REIT) Hammerson is expect
Read moreTuesday broker round-up
17th Jul 2012 08:15
ARM: Citigroup cuts target from 730p to 600p, buy recommendation maintained. AstraZeneca: Bernstein reduces target from 3,037p to 3,002p, market perform rating kept. Beazley: JP Morgan Cazenove raises target from 147p to 155p, neutral rating kept. Bodycote: JP Morgan Cazenove cuts target from 437
Read moreTuesday broker round-up - UPDATE
10th Jul 2012 08:18
WPP: JP Morgan upgrades to outperform from neutral. AMEC: BarCap raises target from 1,340p to 1,350p, underweight rating kept. ASOS: Peel Hunt keeps buy rating and 1,800p target. AstraZeneca: BarCap keeps equal weight rating. Betfair: Nomura cuts target from 1,070p to 946p, buy rating unchanged.
Read moreLondon close: US jobs data sinks stocks
6th Jul 2012 16:41
- US non-farm payrolls disappoint - Miners drag the Footsie lower - IMF to cut global GDP forecast After treading water for the morning session, the Footsie dropped in afternoon trade after a disappointing employment report from the US dampened the outlook for the global economy. The US Labor Depa
Read moreLondon midday: Stocks fall as investors shrug off central bank action
6th Jul 2012 11:37
- Markets look ahead to US jobs report - Investors shrug off central bank action - Aviva jumps on Delta Lloyds disposal The Footsie was trading within a narrow range on Friday morning as investors showed caution ahead of a pivotal employment report due out in the US in the coming hours. Stocks o
Read moreBroker tips: AstraZeneca, AB Foods, Dunelm
6th Jul 2012 11:31
Jefferies has downgraded its recommendation for pharmaceuticals giant AstraZeneca from 'buy' to hold' after the recent strong performance in the shares. "The shares have traded as low as 2,578p during the last few months as weak markets and irrational fears over potential large-scale M&A that could
Read moreBroker snap: AstraZeneca downgraded by Jefferies
6th Jul 2012 10:48
Jefferies has downgraded its recommendation for pharmaceuticals giant AstraZeneca from 'buy' to hold' after the recent strong performance in the shares. "The shares have traded as low as 2,578p during the last few months as weak markets and irrational fears over potential large-scale M&A that could
Read moreFriday broker round-up
6th Jul 2012 09:35
Aviva: SocGen upgrades to hold from sell. Aberdeen: UBS cuts target from 310p to 300p, buy rating unchanged. Associated British Foods: Nomura raises target from 1,375p to 1,400p, buy recommendation unchanged. AstraZeneca: Jefferies downgrades from buy to hold, target left at 2,975p. AVEVA: Beren
Read moreTuesday tips round-up: Segro, AstraZeneca, Soco International
3rd Jul 2012 06:54
Industrial estates don't often set the heart racing but Questor in the Telegraph is rather partial to the logistics hubs owned by property firm Segro. The firm has just spent 130m pounds on a portfolio of warehouse estates in Paris and Lyon. This may look risky in the current euro-infected climate
Read moreLondon midday: Footsie advances as Barclays rebounds
2nd Jul 2012 11:41
- Better-than-expected manufacturing data from Asia - Eurozone jobless rate at all-time high - UK manufacturing PMI beats forecasts London's blue-chip index held on to gains on Monday morning with Barclays leading the risers as it continues to rebound after last week's sharp falls. Economic data f
Read more